On March 15, 2022, the FDA granted approval to Mylan Pharmaceuticals, Inc. for the first generic of the combination product, Symbicort® (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. Symbicort® is one of the most commonly prescribed products for the treatment of respiratory diseases. It consists of two different ingredients; budesonide (a corticosteroid to reduce inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing). Symbicort® is approved for use in the treatment of asthma in patients six years and older, and for the maintenance treatment of patients with chronic obstruction pulmonary disease (COPD). Asthma is a chronic lung disease that can start at any age and causes the airways in the lungs to become swollen and extra sensitive to certain environmental “triggers,” like allergens and pollutants. This inflammation makes it difficult to move air in and out of the lungs and causes symptoms such as shortness of breath, chest tightness, coughing or wheezing. COPD (e.g., chronic bronchitis and emphysema) is a chronic, but preventable and treatable disease that causes the airways in the lungs to become inflamed and thickened, which makes it more difficult for the lungs to deliver oxygen to the rest of the body and to remove carbon dioxide waste. This results in symptoms such as chronic cough, shortness of breath, frequent infections, increased production of mucus and wheezing. The budesonide and formoterol inhaler works to improve breathing by opening the airways and reducing inflammation caused by these conditions. It is typically dosed as two inhalations given twice daily, at morning and night about 12 hours apart. It is available in two different strengths; a high dose version which provides 160/4.5 mcg of each product per actuation, and a low dose version which provides 80/4.5 mcg per actuation. Symbicort® was previously available as a branded product and as an authorized generic (same product as the brand name but without the brand label). This approval of generic Symbicort will give providers another treatment option for their patients and increase access to safe, effective, and affordable medications for the consumer.